Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/leu200858.pdf
Reference21 articles.
1. Wilhelm S, Chien DS . BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8: 2255–2257.
2. Ahmad T, Eisen T . Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10: 6388S–6392S.
3. Wilhelm SM, Carter C, Tang L, Wikie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109.
4. Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007; 21: 439–445.
5. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J . The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007; 92: 27–34.
Cited by 91 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Multifaceted Functionality of Plasmacytoid Dendritic Cells in Gastrointestinal Cancers: A Potential Therapeutic Target?;Cancers;2024-06-13
2. TLR3 activation enhances sorafenib-antitumor effect in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways;2024-04-08
3. IFNB induced by non-lytic virus immunotherapy promotes improved survival in hepatocellular carcinoma, mediated by MHCII-independent cytotoxic CD4+ T-cells;2024-02-23
4. Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways;Heliyon;2023-08
5. Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma;BMC Cancer;2022-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3